AUR-AD9F-TTM2-A-1-1-R-A542-39
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.530
- IL6_JAK_STAT3_SIGNALING+0.470
- INTERFERON_GAMMA_RESPONSE+0.410
- COMPLEMENT+0.350
- INTERFERON_ALPHA_RESPONSE+0.340
- IL2_STAT5_SIGNALING+0.320
- KRAS_SIGNALING_UP+0.290
- INFLAMMATORY_RESPONSE+0.230
- APOPTOSIS+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
Top 10 suppressed
- MYC_TARGETS_V1-0.430
- PROTEIN_SECRETION-0.320
- CHOLESTEROL_HOMEOSTASIS-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.280
- GLYCOLYSIS-0.270
- MTORC1_SIGNALING-0.250
- MYC_TARGETS_V2-0.250
- OXIDATIVE_PHOSPHORYLATION-0.200
- G2M_CHECKPOINT-0.190
- PEROXISOME-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-PE-A5DE-01A-11R-A27Q-07 | — | D | 0.859 |
| 2 | MNG303 | — | — | 0.851 |
| 3 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.851 |
| 4 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.847 |
| 5 | TCGA-AC-A2FE-01A-11R-A19W-07 | — | A | 0.837 |
| 6 | MNG728 | — | — | 0.833 |
| 7 | BS_JBGZ7HHZ | ganglioneuroblastoma | — | 0.833 |
| 8 | SRR8518127 | — | D | 0.833 |
| 9 | TCGA-BH-A0B6-01A-11R-A19W-07 | — | D | 0.829 |
| 10 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |